Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Rocatinlimab · AMG-451, KHK-4083

Monoclonal antibody · Acts on OX40 (TNFRSF4) (TNFRSF4) · developed by AMGEN

Phase 1 Most advanced trial (none active)
AMGN Developer
1 Registered trials

What is Rocatinlimab?

Rocatinlimab is a subcutaneously injected antibody studied in atopic dermatitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AMG-451, KHK-4083
Drug type
Monoclonal antibody
Targets
OX40 (TNFRSF4) (TNFRSF4)
Mechanism
Acts on OX40 (TNFRSF4) (TNFRSF4)
Therapy area
Dermatology, Immunology
Developer
AMGEN (AMGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
G770V925KP

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06268860 Phase 1 Atopic Dermatitis Completed AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atopic Dermatitis

Other drugs acting on TNFRSF4

More from AMGEN

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Rocatinlimab

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.